Legal Representation
Attorney
Michael K. Kelly
USPTO Deadlines
Application History
8 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 8, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 8, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 8, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 1, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 25, 2025 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Sep 25, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 19, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| May 19, 2025 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Biotechnology research; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development in the field of Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), Frontotemporal Dementia (FTD), Huntington’s Disease, and vascular dementia; Scientific research for medical purposes in the field of Central Nervous System (CNS) disorders; Scientific study and research in the field(s) of treatment and management of CNS disorders; Laboratory research services relating to pharmaceuticals; Clinical research in the field of Central Nervous System (CNS) disorders medical treatment; Testing of pharmaceuticals; Scientific research in the nature of conducting clinical trials for others in the field of Central Nervous System (CNS) disorders treatments; Research and development services in the field of pharmaceutical preparations; Laboratory services for biomanufacturing CRO-contracted compounds; Laboratory research in the field of chemical analyses for analog development and PK/PD profiling; Pharmaceutical research and development; Conducting early evaluations in the field of new pharmaceuticals; Research and development and consultation related thereto in the field of pharmaceutical therapeutic strategy and trial design advisory; Medical and scientific research in the field of Amyotrophic Lateral Sclerosis (ALS)
First Use Anywhere:
Apr 20, 2025
First Use in Commerce:
Apr 20, 2025
Class 044
Providing medical information in the field of Amyotrophic Lateral Sclerosis (ALS); Pharmaceutical advice; Providing health information in the field of Central Nervous System (CNS) disorders; Medical analysis services relating to the treatment of persons; Providing information in the field of the diagnosis and treatment of Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), Frontotemporal Dementia (FTD), Huntington’s Disease, and vascular dementia via a website; Consulting services in the field of the diagnosis and treatment of Amyotrophic Lateral Sclerosis (ALS); Consulting services to health care providers in the field of treating life-changing or life-threatening diseases; Medical testing for diagnostic or treatment purposes; Medical testing for diagnostic or treatment purposes in the field of Central Nervous System (CNS) disorders; Medical screening services in the field of Central Nervous System (CNS) disorders
First Use Anywhere:
Apr 20, 2025
First Use in Commerce:
Apr 20, 2025
Additional Information
Design Mark
The mark consists of the stylized words "CORTEXA" and "THERAPEUTICS", where "CORTEXA" is larger than, and directly above, "THERAPEUTICS". A circle containing an abstract design is centered directly above "CORTEXA".
Classification
International Classes
042
044